BRAVO Iannis!! Excellent job!!!
RT @iannisaifantis1@twitter.com
2022 ends with a bang...after years of work our immune single cell (CITE/TCR-Seq) mapping of adult and pediatric AML is our today @NatureCancer@twitter.com ! The work was headed by two stars in the #AifantisLab, @audrey_lasry@twitter.com & @BettinaNadorp@twitter.com #leukemia (1/5)
https://www.nature.com/articles/s43018-022-00480-0
🐦🔗: https://twitter.com/iannisaifantis1/status/1608581080092934144
RT @iannisaifantis1
2022 ends with a bang...after years of work our immune single cell (CITE/TCR-Seq) mapping of adult and pediatric AML is our today @NatureCancer ! The work was headed by two stars in the #AifantisLab, @audrey_lasry & @BettinaNadorp #leukemia (1/5)
https://www.nature.com/articles/s43018-022-00480-0
RT @iannisaifantis1@twitter.com
2022 ends with a bang...after years of work our immune single cell (CITE/TCR-Seq) mapping of adult and pediatric AML is our today @NatureCancer@twitter.com ! The work was headed by two stars in the #AifantisLab, @audrey_lasry@twitter.com & @BettinaNadorp@twitter.com #leukemia (1/5)
https://www.nature.com/articles/s43018-022-00480-0
🐦🔗: https://twitter.com/iannisaifantis1/status/1608581080092934144
RT @iannisaifantis1@twitter.com
2022 ends with a bang...after years of work our immune single cell (CITE/TCR-Seq) mapping of adult and pediatric AML is our today @NatureCancer@twitter.com ! The work was headed by two stars in the #AifantisLab, @audrey_lasry@twitter.com & @BettinaNadorp@twitter.com #leukemia (1/5)
https://www.nature.com/articles/s43018-022-00480-0
🐦🔗: https://twitter.com/iannisaifantis1/status/1608581080092934144